PEGylation of Proteins: A Structural Approach - Structural properties of PEGylated proteins could play an increasingly important role in developing optimal therapeutic protein drugs. - BioPharm


PEGylation of Proteins: A Structural Approach
Structural properties of PEGylated proteins could play an increasingly important role in developing optimal therapeutic protein drugs.

BioPharm International
Volume 19, Issue 4

21. Jeppesen C, et al. Impact of polymer tether length on multiple ligand-receptor bond formation. Science 2001, 293:465-68.

22. Fee CJ, Van Alstine JM, Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins. Bioconj. Chem. 2004;15:1304-13.

23. Digilio G, et al. NMR structure of two novel polyethylene glycol conjugates of the human growth hormone-releasing factor, hGRF(1-29) -NH2. J. Am. Chem, Soc. 2003;125:3458-70.

24. Greenwald RB. Poly(ethylene glycol) anticancer drug delivery systems. P. R. Health Sci. J. 2002, 21:113-121.

25. Hinds KD, Kim SW. Effects of PEG conjugation on insulin properties. Adv. Drug Deliv. Rev. 2002;54:505-30.

26. Mehvar R. Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. J. Pharm. Pharm. Sci. 2000, 3:125-136.

27. Lee KC, et al. Isolation, characterization, and stability of positional isomers of mono-PEGylated salmon calcitonins. Pharm. Res. 1999, 16:813-18.

28. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 2001, 40:539-51.

29. Morpurgo M, et al. Preparation of characterization of poly(ethylene glycol) vinyl sulfone. Bioconjug. Chem. 1996, 7:363-68.

30. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev. 2002, 54:459-76.

31. Veronese FM. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 2001, 22:405-17.

32. Wylie DC, et al. Carboxyalkylated histidine is a pH-dependent product of pegylation with SC-PEG. Pharm. Res. 2001, 18:1354-60.

33. Harris JM. Synthesis of polyethylene glycol derivatives. J. Macromol. Sci. Rev. Macromol. Chem. Phys. 1985, C25:325-73.

34. Wheelwright SM. Protein purification: design and scale up of downstream processing. New York: Whiley;1994.

35. Garcia-Arellano H, et al. High temperature biocatalysis by chemically modified cytochrome c. Bioconjug. Chem. 2002, 13:1336-44.

36. Eiteman MA, Hassinen C, Veide A. A mathematical model to predict the partitioning of peptides and peptide-modified proteins in aqueous two-phase systems. Biotechnol. Prog. 1994, 10:513-19.

37. Abbott NL, Blankschtein D, Hatton TA. Protein partitioning in two-phase aqueous polymer systems. A neutron scattering investigation of the polymer solution structure and protein-polymer interactions. Macromol. 1992, 25:3932-41.

38. Kerwin BA, et al. Interactions between PEG and type I soluble tumor necrosis factor receptor: modulation by pH and by PEGylation at the N terminus. Protein Sci. 2002, 11:1825-33.

39. Bailon P, Berthold W. Polyethylene glycol-conjugated pharmaceutical proteins. Pharm. Sci. Technol. Today 1998, 1:352-56.

40. Roberts MJ, Harris JM. Attachment of degradable poly(ethylene glycol) to proteins has the potential to increase therapeutic efficacy. J. Pharm. Sci. 1998, 87:1440-45.

41. Campbell RM, et al. Pegylated peptides. V. Carboxy-terminal PEGylated analogs of growth hormone-releasing factor (GRF) display enhanced duration of biological activity in vivo. J. Pept. Res. 1997, 49:527-37.

42. Sato H. Enzymatic procedure for site-specific pegylation of proteins. Adv. Drug Deliv. Rev. 2002, 54:487-504.

43. Yamamoto Y, et al. Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity. Nat. Biotechnol. 2003, 21:546-52.

blog comments powered by Disqus



Pandemic Vaccine Facility Dedicated in Texas
September 19, 2014
GSK Fined in China Bribery Scandal
September 19, 2014
Guideline Delineates How to Implement GS1 Standards to Support DSCSA
September 19, 2014
GPhA Supports Restricted Access Bill
September 18, 2014
Baxter Initiates Voluntary Recall of Potassium Chloride Injection
September 17, 2014
Author Guidelines
Source: BioPharm International,
Click here